Supernus (SUPN) CFO awarded 17,500 options and 3,000 RSUs in equity grant

Rhea-AI Filing Summary

Supernus Pharmaceuticals reported that Senior Vice-President & CFO Timothy C. Dec received new equity awards. He was granted employee stock options for 17,500 shares at a price of $0.00 per share, which vest in four equal annual installments beginning on February 18, 2027. He also received 3,000 restricted stock units, each representing one share of common stock, vesting in four equal annual installments starting on the same date and settled in common stock upon vesting. Following these awards, he directly holds 1,638 shares of common stock, including an aggregate of 392 shares acquired through the company’s Employee Stock Purchase Plan.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider DEC TIMOTHY C

Role Senior Vice-President & CFO

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	17,500	$0.00	--
Grant/Award	Restricted Stock Unit	3,000	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 17,500 shares (Direct); Restricted Stock Unit — 3,000 shares (Direct); Common Stock — 1,638 shares (Direct)

Footnotes (1)

1. Includes an aggregate of 392 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. The option vests in four equal annual installments beginning on February 18, 2027. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DEC TIMOTHY C

(Last) (First) (Middle)

C/O SUPERNUS PHARMACEUTICALS, INC.

9715 KEY WEST AVENUE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice-President & CFO

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								1,638(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$50.2	02/18/2026		A		17,500		(2)	02/18/2036	Common Stock	17,500	$0	17,500	D
Restricted Stock Unit	(3)	02/18/2026		A		3,000		(4)	(4)	Common Stock	3,000	$0	3,000	D

Explanation of Responses:

1. Includes an aggregate of 392 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.

2. The option vests in four equal annual installments beginning on February 18, 2027.

3. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

4. These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027.

Remarks:

	/s/ Timothy C. Dec	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Supernus (SUPN) grant to its CFO Timothy C. Dec?

Supernus granted CFO Timothy C. Dec stock options for 17,500 shares and 3,000 restricted stock units. Both awards were granted at a price of $0.00 per share and represent additional equity-based compensation tied to future vesting conditions.

How do Timothy C. Dec’s new stock options at Supernus (SUPN) vest?

The 17,500 stock options granted to Timothy C. Dec vest in four equal annual installments. Vesting begins on February 18, 2027, meaning portions of the award become exercisable each year over a four-year period, aligning compensation with longer-term company performance.

What are the terms of the restricted stock units granted by Supernus (SUPN)?

Supernus granted 3,000 restricted stock units, each representing one share of common stock upon vesting. These units vest in four equal annual installments starting on February 18, 2027, and are settled in common stock, providing the executive with shares over time.

How many Supernus (SUPN) common shares does Timothy C. Dec now hold directly?

After the reported transactions, Timothy C. Dec directly holds 1,638 shares of Supernus common stock. This total includes 392 shares acquired through the company’s Employee Stock Purchase Plan, reflecting his ongoing participation in equity ownership programs.

Does the Supernus (SUPN) Form 4 show any stock sales by Timothy C. Dec?

The Form 4 shows only grant or award acquisitions of options and restricted stock units, with no reported sales. Transactions are coded as awards (code A), indicating additional equity-based compensation rather than open-market buying or selling of existing shares.

What does each restricted stock unit in the Supernus (SUPN) grant represent?

Each restricted stock unit granted to Timothy C. Dec represents the right to receive one share of Supernus common stock upon vesting. Once vesting conditions are met, the units are settled in common stock rather than cash, increasing his share ownership.